# Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)

> **NCT04370873** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 22 (actual)

## Conditions studied

- Pulmonary Hypertension

## Interventions

- **DRUG:** Frespaciguat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04370873
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-05
- **Primary completion:** 2022-01-12
- **Final completion:** 2022-01-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04370873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04370873, "Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT04370873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*